Surgical sympathectomy for Buerger's disease

Area of Science:

• Vascular Surgery
• Pharmacology

Background:

• Buerger's disease involves progressive inflammation and occlusion of small and medium limb arteries and veins.
• Tobacco use is a primary risk factor, leading to ischemic ulcers and severe pain.
• Surgical revascularization is often not feasible, necessitating alternative treatments like sympathectomy.

Purpose of the Study:

• To compare the effectiveness of surgical sympathectomy with other therapies for Buerger's disease.
• Specifically, to evaluate intravenous iloprost against lumbar sympathectomy in managing ischemic ulcers and pain.

Main Methods:

• A systematic review was conducted, focusing on randomized controlled trials comparing sympathectomy with other treatments.
• One study (162 participants) comparing lumbar sympathectomy with intravenous iloprost was included.
• Outcomes assessed included ulcer healing and pain relief at four and twenty-four weeks.

Main Results:

• Intravenous iloprost demonstrated higher effectiveness in complete ulcer healing at four and twenty-four weeks compared to sympathectomy (very low quality evidence).
• Iloprost also showed greater effectiveness in relieving rest pain at four weeks (very low quality evidence).
• No significant difference in pain relief was observed at twenty-four weeks.

Conclusions:

• Based on very low quality evidence, intravenous iloprost appears more effective than lumbar sympathectomy for Buerger's disease patients regarding ulcer healing and rest pain.
• Current evidence does not robustly support the routine preference of one treatment over the other.
• Further high-quality research is needed to establish definitive treatment guidelines.